COVID-19 oral antivirals in general practice (webinar held 20 June 2022)

Please note the information in this webinar was correct at the time of recording. ThE PBS criteria for COVID-19 oral antivirals have now changed. Please visit the Australian Department of Health website for the latest information: https://www.health.gov.au/health-aler... With the COVID-19 antivirals Paxlovid and Lagevrio now listed on the Pharmaceutical Benefits Scheme (PBS), GPs play a pivotal role in managing patients with COVID-19 infections. However, there are significant challenges in prescribing these medications. Our expert panel included a respiratory specialist, a GP and a community pharmacist. They provided the latest evidence, hands-on experience and case studies on long COVID-19, and answered questions from the audience. By the end of the session you will be able to: describe the patient populations eligible for antivirals list the appropriate PBS criteria, dosage, and contraindications to the antivirals identify pathways for accessing COVID-19 oral antiviral therapy identify the challenges to prescribing in the general practice setting and how to overcome them. 00:00 – Introduction 04:30 – About the antiviral medications and their effectiveness 31:10 – Practical tips for prescribing 50:44 – Questions for the panel